WO2001019817A3 - 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission - Google Patents

3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission Download PDF

Info

Publication number
WO2001019817A3
WO2001019817A3 PCT/US2000/025444 US0025444W WO0119817A3 WO 2001019817 A3 WO2001019817 A3 WO 2001019817A3 US 0025444 W US0025444 W US 0025444W WO 0119817 A3 WO0119817 A3 WO 0119817A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolidinyloxy
ether compounds
compounds useful
synaptic transmission
controlling chemical
Prior art date
Application number
PCT/US2000/025444
Other languages
French (fr)
Other versions
WO2001019817A2 (en
Inventor
Nan-Horng Lin
Yihong Li
Irene Drizin
John F Kincaid
Anwer Basha
Liming Dong
Ahmed A Hakeem
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to CA002381252A priority Critical patent/CA2381252A1/en
Priority to EP00965070A priority patent/EP1212319A2/en
Priority to MXPA02002115A priority patent/MXPA02002115A/en
Priority to JP2001523394A priority patent/JP2003529547A/en
Publication of WO2001019817A2 publication Critical patent/WO2001019817A2/en
Publication of WO2001019817A3 publication Critical patent/WO2001019817A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A series of 3-pyrrolidinyloxy-3'-pyridyl ether compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions including these compounds. Preferred compounds are 3-pyrrolidinylmethoxy-3'-(5'-and/or 6'-substituted) pyridyl ethers.
PCT/US2000/025444 1999-09-14 2000-09-14 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission WO2001019817A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002381252A CA2381252A1 (en) 1999-09-14 2000-09-14 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
EP00965070A EP1212319A2 (en) 1999-09-14 2000-09-14 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
MXPA02002115A MXPA02002115A (en) 1999-09-14 2000-09-14 3-pyrrolidinyloxy-3 -pyridyl ether compounds useful for controlling chemical synaptic transmission.
JP2001523394A JP2003529547A (en) 1999-09-14 2000-09-14 3-Pyrrolidinyloxy-3'-pyridyl ether compounds effective for controlling chemical synaptic transmission

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39514699A 1999-09-14 1999-09-14
US09/395,146 1999-09-14

Publications (2)

Publication Number Publication Date
WO2001019817A2 WO2001019817A2 (en) 2001-03-22
WO2001019817A3 true WO2001019817A3 (en) 2002-01-17

Family

ID=23561895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025444 WO2001019817A2 (en) 1999-09-14 2000-09-14 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission

Country Status (5)

Country Link
EP (1) EP1212319A2 (en)
JP (1) JP2003529547A (en)
CA (1) CA2381252A1 (en)
MX (1) MXPA02002115A (en)
WO (1) WO2001019817A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562847B1 (en) 1998-08-25 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
DE10135043A1 (en) * 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituted 3-heteroaryl (amino or oxy) pyrrolidin-2-ones, process for their preparation and use as herbicides or as plant growth regulators
AU2002353147A1 (en) * 2001-12-13 2003-06-30 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
EP1546116A1 (en) 2002-08-08 2005-06-29 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1670794A2 (en) * 2003-09-30 2006-06-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
ATE471320T1 (en) 2004-02-27 2010-07-15 Lilly Co Eli 4-AMINOPIPERIDINE DERIVATIVES AS INHIBITORS OF MONOAMINE ABSORPTION
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
KR100939347B1 (en) 2005-07-20 2010-01-29 (주)카이로드 Synthetic Method of optically pure S-3-hydroxypyrrolidine
CN102112469B (en) * 2008-05-23 2014-09-10 乔治敦大学 Silent desensitizers of neuronal nAChR and methods of use thereof
WO2010045212A2 (en) * 2008-10-14 2010-04-22 Psychogenics, Incstatuts Nicotinic acetylcholine receptor ligands and the uses thereof
AR075988A1 (en) 2009-04-09 2011-05-11 Lilly Co Eli PIRIDYLOXI COMPOUND - PIRROLIDINE INHIBITOR OF RECOVERY OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC PAIN
JP2013512922A (en) 2009-12-07 2013-04-18 ターガセプト，インコーポレイテッド 3,6-diazabicyclo [3.1.1] heptane as a neuronal nicotinic acetylcholine receptor ligand
EP2544690A4 (en) * 2010-03-11 2013-07-10 Targacept Inc Arylvinylazacycloalkane compounds for constipation
ES2903528T3 (en) * 2016-10-10 2022-04-04 Dong A Socio Holdings Co Ltd Heteroaryl compounds and their use as MER inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107930A2 (en) * 1982-09-30 1984-05-09 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine
US4643995A (en) * 1983-12-28 1987-02-17 Degussa Aktiengesellschaft Analgesic pyridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4667031A (en) * 1985-10-15 1987-05-19 Ethyl Corporation Process for preparing oxazepinones
WO1994008992A1 (en) * 1992-10-09 1994-04-28 Abbott Laboratories Heterocyclic ether compounds that enhance cognitive function
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1999024422A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
WO2000010997A1 (en) * 1998-08-25 2000-03-02 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107930A2 (en) * 1982-09-30 1984-05-09 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine
US4643995A (en) * 1983-12-28 1987-02-17 Degussa Aktiengesellschaft Analgesic pyridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4667031A (en) * 1985-10-15 1987-05-19 Ethyl Corporation Process for preparing oxazepinones
WO1994008992A1 (en) * 1992-10-09 1994-04-28 Abbott Laboratories Heterocyclic ether compounds that enhance cognitive function
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1999024422A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
WO2000010997A1 (en) * 1998-08-25 2000-03-02 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application

Also Published As

Publication number Publication date
CA2381252A1 (en) 2001-03-22
EP1212319A2 (en) 2002-06-12
MXPA02002115A (en) 2002-10-31
JP2003529547A (en) 2003-10-07
WO2001019817A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
WO2001019817A3 (en) 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
DK1080641T3 (en) Preparation and Method for Controlling Biological Growth Using Stabilized Sodium Hypbromite in Synergistic Combinations
AU3897197A (en) Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU2002224424A1 (en) Method and apparatus for providing optical internetworking to wide area networks, metropolitan area networks, and local area networks using modular components
AU2001288719A1 (en) System and method for collaboration using web browsers
AU2001287003A1 (en) System and method for collaboration using web browsers
AU2001261385A1 (en) Method and apparatus for using scatterometry to perform feedback and feed-forward control
AU2002233955A1 (en) Network and method for trading derivatives
AU2002225906A1 (en) Method for the preparation of a poly(arylene ether)-polyolefin composition, and composition prepared thereby
AU2001277901A1 (en) System and method for establishing business to business connections via the internet
AU2028001A (en) Personalized investment consulting system implemented on network and method for the same
AU2002220150A1 (en) Method and apparatus for event-based network administration
AU2001226354A1 (en) Fixative system, method and composition for biological testing
AU2001295743A1 (en) System, apparatus and method for personalising web content
AU2001277602A1 (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same
AU6770100A (en) Adjustable-backset latch system for locksets, and method
AU5912596A (en) Oxidized polymeric carbohydrate ethers for use as sequesteri ng agent, and methods for the preparation thereof
AU2002223690A1 (en) Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate
AU2001234772A1 (en) Method for obtaining and evaluating neuro feedback
ZA200005182B (en) Substituted piperidines, method for their preparation and their use as pesticides and fungicides.
AU4907600A (en) Method for engineering paths for multicast traffic
DK0838469T3 (en) 10,13,15-Trioxatricyclo (9.2.1 9.6) -pentadecanone derivatives, process for their preparation, and drugs containing these compounds
AU2159797A (en) Substituted pyridines/pyrimidines, process for the preparation thereof and use thereof as pesticides
ZA976329B (en) Substituted pyrazolylpyrazole derivatives, process for their preparation, and their use as herbicides.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2381252

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002115

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523394

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000965070

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965070

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000965070

Country of ref document: EP